Determining the antiviral properties and mechanism of actions of BOLD-100 against SARS-CoV-2 in 2D and 3D cell culture systems

BOLD-100 is a promising new clinical stage therapeutic, originally developed for the use as a cancer treatment. The mechanism of action for BOLD-100 suggests that this therapeutic might also protect against infections with viruses, including coronaviruses like SARS-COV-19. The purpose of this project is to test the antiviral efficacy of BOLD-100 against SARS·COV-19 in 20 […]

Read More
Investigations into the mechanism of action and potential in idiopathic pulmonary fibrosis of the novel ruthenium based therapeutic BOLD-100

Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease lung disease with unknown cause. There are limited treatment options for IPF and investigations into new treatment options is needed. BOLD-100 is a clinical-stage small molecule that is currently being investigated as a treatment option in oncology and viral infections. The pathway that BOLD-100 impacts, […]

Read More